Our Mission

Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing, and commercializing products that treat inflammation and inborn errors of metabolism. Aldeyra's lead product candidate, reproxalap (formerly known as ADX-102), is a small molecule aldehyde sequestering agent in Phase 2b clinical development for the treatment of dry eye disease, and Phase 3 clinical development for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome.

Dry Eye Disease

Dry eye disease is a common and chronic inflammatory disease estimated to affect approximately 20 million people in the United States, and is characterized by insufficient moisture and lubrication in the anterior surface of the eye, leading to dryness, inflammation, pain, discomfort, irritation, and, in severe cases, decreased vision. Among physicians and patients, existing therapy for dry eye disease is generally regarded as inadequate. In patients with dry eye disease, pro-inflammatory aldehyde mediators may contribute to ocular inflammation.

Aldeyra Therapeutics reported positive Phase 2a data in Dry Eye Disease (insert link to the press release), then link to disease information for dry eye disease

Allergic Conjunctivitis

Allergic Conjunctivitis is a common allergic disease that affects more than 20% of the population worldwide. The disease is thought to be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation of the conjunctiva (a membrane covering the front part of the eye), resulting in ocular itching and excessive tear production.

Noninfectious Anterior Uveitis

Noninfectious Anterior Uveitis is a rare but severe and potentially blinding inflammatory disease characterized in part by high aldehyde levels that may cause increased numbers of inflammatory cells in the front of the eye, leading to pain, redness, loss of vision, and other ocular symptoms.

Sjögren-Larsson Syndrome 

Succinic Semi-aldehyde Dehydrogenase Deficiency 

Semi-aldehyde Dehydrogenase Deficiency, a neurological disease caused by genetic mutations that result in elevated levels of succinic semi-aldehyde, a toxic aldehyde that is converted to other metabolites that can cause severe neurological dysfunction.

Learn more about Aldeyra Therapeutics: